Meridian Bioscience, Inc. (VIVO) |
| 33.97 0 (0%) 01-30 16:00 |
| Open: | 33.95 |
| High: | 34.01 |
| Low: | 33.95 |
| Volume: | 5,627,450 |
| Market Cap: | 1,489(M) |
| PE Ratio: | 21.09 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 39.72 |
| Resistance 1: | 34.01 |
| Pivot price: | 33.78 |
| Support 1: | 33.44 |
| Support 2: | 33.09 |
| 52w High: | 34.375 |
| 52w Low: | 23.4438 |
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
| EPS | 1.610 |
| Book Value | 6.470 |
| PEG Ratio | 2.56 |
| Gross Profit | 4.298 |
| Profit Margin (%) | 12.75 |
| Operating Margin (%) | 22.70 |
| Return on Assets (ttm) | 10.4 |
| Return on Equity (ttm) | 12.2 |
Sat, 03 Jan 2026
NeoGenomics Adds Diagnostics Executive Jack Kenny To Board - Pulse 2.0
Tue, 30 Dec 2025
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors - Business Wire
Wed, 14 Dec 2022
SD Biosensor postpones closing of $1.53B Meridian acquisition to complete financing - MedTech Dive
Fri, 29 Jul 2022
FDA re-authorizes Meridian Bioscience’s COVID-19 assay - MassDevice
Mon, 18 Jul 2022
All the details behind Meridian Bioscience's pending $1.53B acquisition - The Business Journals
Thu, 07 Jul 2022
Press Telegram - FinancialContent
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |